Hubei Biocause Pharmaceutical Co., Ltd.

XSEC:000627 Stock Report

Market Cap: CN¥24.8b

Hubei Biocause Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Hubei Biocause Pharmaceutical's earnings have been declining at an average annual rate of -69.5%, while the Insurance industry saw earnings growing at 10.6% annually. Revenues have been growing at an average rate of 1.8% per year.

Key information

-69.5%

Earnings growth rate

-68.9%

EPS growth rate

Insurance Industry Growth-3.0%
Revenue growth rate1.8%
Return on equity-4.2%
Net Margin-1.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hubei Biocause Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:000627 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2440,698-7721,3360
30 Jun 2443,915-8291,7750
31 Mar 2443,814-7871,7150
31 Dec 2348,278-6521,7590
30 Sep 2352,784-1771,8670
30 Jun 2355,172-891,7870
31 Mar 2353,0281721,7130
01 Jan 2349,3122741,6460
30 Sep 2250,9753561,3270
30 Jun 2253,3863321,8370
31 Mar 2254,2343931,7880
01 Jan 2248,6974711,4210
30 Sep 2141,9403577220
30 Jun 2137,020375-6970
31 Mar 2136,212420-1,9420
31 Dec 2041,128580-1,6730
30 Sep 2041,8251,335-7050
30 Jun 2043,4831,5491890
31 Mar 2044,5921,8311,9140
31 Dec 1949,6731,7762,1120
30 Sep 1948,1241,3312,1140
30 Jun 1942,8691,2272,1020
31 Mar 1936,7571,3171,7280
31 Dec 1829,8791,3271,6410
30 Sep 1831,0101,4994180
30 Jun 1835,3431,5489580
31 Mar 1845,2561,5541,3660
31 Dec 1753,4021,3261,3900
30 Sep 1754,8191,7752,5850
30 Jun 1749,4121,5741,9650
31 Mar 1738,4141,0951,5290
31 Dec 1616,9891,7791,2180
30 Sep 169,4401,1467490
30 Jun 166,5691,1154580
31 Mar 163,4391,0611640
31 Dec 151,080247720
30 Sep 15916-119730
30 Jun 15978-130690
31 Mar 151,053-131730
31 Dec 141,13584700
30 Sep 1492281680
30 Jun 141,01394710
31 Mar 141,04399670
31 Dec 13968-101680

Quality Earnings: 000627 is currently unprofitable.

Growing Profit Margin: 000627 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 000627 is unprofitable, and losses have increased over the past 5 years at a rate of 69.5% per year.

Accelerating Growth: Unable to compare 000627's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 000627 is unprofitable, making it difficult to compare its past year earnings growth to the Insurance industry (16.2%).

Return on Equity

High ROE: 000627 has a negative Return on Equity (-4.18%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 13:46
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hubei Biocause Pharmaceutical Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jun LiuChangjiang Securities Co. LTD.
Yeyong MengSWS Research Co., Ltd.